ASX Healthcare Companies Snapshot – 4DMedical Limited | Actinogen Medical Limited | Neuren Pharmaceuticals Limited | Oneview Healthcare PLC - An Introduction
- Noel Ong
- 10 hours ago
- 10 min read
Since Samso started to look at the Australian healthcare sector, the Samso platform has started to appreciate the investor attention in the sector as companies progress from early development into clinical validation, regulatory approval, and commercialisation. This Samso Insights ASX Companies Snapshot & Market Position provides a brief, side-by-side overview of selected ASX-listed healthcare companies, outlining what each business does, where it sits within the market, and how it is currently positioned from a market capitalisation and execution perspective.
💊4DMedical Limited
4DMedical Limited (ASX: 4DX) is an Australian-listed medical technology company focused on advancing the diagnosis and management of respiratory disease through functional lung imaging. Headquartered in Melbourne with a growing presence in the United States, the company operates at the intersection of medical imaging, software, and artificial intelligence, targeting unmet needs in lung health diagnostics across global healthcare systems.
The Business of the Company
Develops and commercialises software-based lung imaging solutions built on its proprietary XV Technology®, converting standard CT and fluoroscopy scans into functional insights on ventilation and perfusion.
Core product portfolio includes FDA-cleared XV LVAS® and CT LVAS™, alongside flagship CT:VQ™, which delivers combined ventilation and perfusion analysis from routine non-contrast CT scans (Figure 1).
Products are delivered via a Software-as-a-Service (SaaS) model, integrating directly into existing hospital workflows and PACS systems without requiring new imaging hardware.
Strategic focus on the U.S. healthcare market, executing an academic medical centre (AMC)-led commercialisation strategy.
Following FDA clearance, CT:VQ™ has been adopted by leading U.S. institutions, including Stanford University, University of Miami, and Cleveland Clinic, establishing high-profile reference sites to support broader market adoption.
Figure 1: CT:VQ™ - Coronal CT images of ventilation and perfusion (source: 4DX)
Market Standing
Market Capitalisation: ~$2.14 billion (as of early January 2026), reflecting a material re-rating from earlier stages of the company’s commercial lifecycle.
Industry Group: Health
ASX Listing Date: 7 August 2020, providing public market exposure during the transition from technology development through regulatory clearance and into early commercial deployment.
Share price performance shows a sharp upward re-rating from late 2025 into early January 2026, accompanied by elevated trading volumes, indicating increased market participation and investor attention (Figure 2).
Figure 2: 4DX’s Share Price & Trading Volume (Jan 2025 – Jan 2026) (source: ASX)
💊Actinogen Medical Limited
Actinogen Medical Limited (ASX: ACW) is an Australian-listed biotechnology company focused on the development of novel therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. Headquartered in Sydney, the company is advancing a differentiated central nervous system (CNS) drug development program targeting large, high-unmet-need indications, with its primary focus on Alzheimer’s disease.
The Business of the Company
Focused on the development of its lead drug candidate Xanamem® (emestedastat), a first-in-class, oral small-molecule therapy targeting excess cortisol within brain cells through inhibition of the 11β-HSD1 enzyme.
Xanamem is being developed primarily for Alzheimer’s disease, with supporting clinical evidence in major depressive disorder and potential applicability across other neurological and psychiatric conditions.
Designed as a once-daily oral therapy that reduces cortisol levels in the brain without interfering with normal systemic cortisol production, which is critical for overall physiological function.
Advancing the XanaMIA Phase 2b/3 clinical trial in mild-to-moderate Alzheimer’s disease, a 36-week, randomised, placebo-controlled study conducted across Australia and the United States (Figure 3).
Full enrolment of 246 participants completed, with an interim safety and efficacy futility analysis expected in late January 2026 and final topline results scheduled for November 2026.
An open-label extension study is planned to commence in Q1 2026, aimed at collecting longer-term safety and efficacy data in participants receiving active Xanamem treatment.
Figure 3: XanaMIA Phase 2b/3 Trial Design & Key Clinical Milestones (source: ACW)
Market Standing
Market Capitalisation: ~$210.34 million.
Industry Group: Pharmaceuticals, Biotechnology & Life Sciences.
ASX Listing Date: 16 October 2007, providing long-standing public market exposure through multiple clinical development cycles.
The share price shows a steady upward trend from late December 2025 into early January 2026, supported by periodic increases in trading volume, indicating growing market interest ahead of key clinical milestones (Figure 4).
Figure 4: ACW’s Share Price & Trading Volume (Jan 2025 – Jan 2026) (source: ASX)
💊Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited (ASX: NEU) is an Australian-listed biotechnology company focused on developing therapies for severe neurodevelopmental disorders with high unmet medical need. The company’s strategy centres on rare and orphan paediatric indications, where well-defined patient populations, clear regulatory pathways, and the potential for accelerated approval frameworks underpin its development approach.
The Business of the Company
Neuren operates a dual-asset model comprising a commercial royalty-generating product and a late-stage clinical development platform.
DAYBUE® (trofinetide) is approved by the U.S. FDA for the treatment of Rett syndrome and is commercialised globally by Acadia Pharmaceuticals under an exclusive licence. Neuren receives tiered royalties on net sales, milestone payments, and other commercial income streams, providing recurring revenue to fund pipeline expansion.
NNZ-2591 is Neuren’s wholly owned, next-generation neurodevelopmental drug candidate. It is an oral synthetic peptide analogue targeting impaired neuronal function and inflammation, designed for chronic administration in paediatric populations.
NNZ-2591 is being advanced as a multi-indication platform, with development programs underway in Phelan-McDermid syndrome (PMS), Pitt Hopkins syndrome (PTHS), Angelman syndrome, SYNGAP1-related disorder, and Hypoxic-Ischaemic Encephalopathy (HIE).
The lead NNZ-2591 program is the Koala Phase 3 trial in Phelan-McDermid syndrome, the first-ever Phase 3 study conducted in this indication, with regulatory alignment already established with the U.S. FDA.
Figure 5: DAYBUE® (trofinetide) (source: NEU)
This structure positions Neuren as a company with near-term cash flow visibility from an approved product alongside multiple late-stage clinical value drivers.
Market Standing
Market Capitalisation: ~$2.40 billion.
Industry Group: Pharmaceuticals, Biotechnology & Life Sciences.
ASX Listing Date: 3 February 2005, reflecting a long-established presence on the ASX and multiple value-creation cycles across drug development and commercialisation.
The share price shows a sustained upward trend through 2025 with elevated trading activity, reflecting continued investor confidence supported by recurring royalty income and late-stage pipeline progress (Figure 6).
Figure 6: NEU’s Share Price & Trading Volume (Jan 2025 – Jan 2026) (source: ASX)
💊Oneview Healthcare PLC
Oneview Healthcare plc (ASX: ONE) is an ASX-listed healthcare technology company focused on enabling the Connected Care Experience within hospitals and healthcare systems. Founded in 2008 and headquartered in Dublin, Ireland, Oneview provides digital platforms that connect the patient room with care teams and hospital systems, aiming to improve patient engagement, clinical workflows, and operational efficiency. The company has an established international footprint across the United States, Australia, Ireland, and Thailand, with a strategic emphasis on the U.S. healthcare market.
The Business of the Company
Oneview develops and commercialises a modular, scalable software platform designed to digitise and integrate the in-room patient experience with hospital clinical and operational systems.
Key elements of the business include:
Delivery of connected care solutions spanning patient engagement, care team workflows, and hospital operations, deployed across televisions, tablets, mobile devices, and bedside systems.
A recurring revenue model driven primarily by software subscriptions, supplemented by deployment and implementation services.
A growing portfolio of AI-enabled products, including Ovie, a generative AI-powered care assistant designed to personalise patient engagement, anticipate needs, and optimise staff workflows (Figure 7).
A commercial model characterised by high customer retention, enterprise-wide expansion opportunities, and strong upsell potential once systems are embedded within hospital environments.
Figure 7: Ovie — Oneview’s Gen AI-Powered Virtual Care Assistant (source: ONE)
Operationally, Oneview tracks performance using live endpoints rather than beds, reflecting the scalable nature of its platform and its ability to monetise multiple devices and interfaces within a single hospital deployment.
Market Standing
Market Capitalisation: ~$306.89 million.
Industry Group: Health Care Equipment & Services.
ASX Listing Date: 17 March 2016, reflecting nearly a decade of public market exposure through the company’s transition from platform development to commercial scale-up.
The share price shows a strong recovery and upward re-rating from October 2025 into early January 2026, accompanied by increased trading volumes, indicating renewed investor interest as commercial execution gains traction (Figure 8).
Figure 8: ONE’s Share Price & Trading Volume (Jan 2025 – Jan 2026) (source: ASX)
💊Cynata Therapeutics Limited
Cynata Therapeutics Limited (ASX: CYP) is an Australian-listed, clinical-stage biotechnology company specialising in cell therapeutics and regenerative medicine. Headquartered in Melbourne, Cynata is focused on developing off-the-shelf mesenchymal stem cell (MSC) therapies using its proprietary Cymerus™ platform, which is designed to overcome the scalability, consistency, and cost limitations of conventional donor-derived cell therapies.
The Business of the Company
Cynata’s business is centred on the development and commercialisation of next-generation MSC therapies derived from induced pluripotent stem cells (iPSCs) via the Cymerus™ platform.
Key elements of the business include:
Cymerus™ platform technology, which produces MSCs from a single donor-derived iPSC master cell bank, enabling large-scale, consistent, and repeatable manufacturing without ongoing donor sourcing.
A diversified clinical pipeline led by CYP-001, Cynata’s intravenous MSC product for acute graft versus host disease (aGvHD), an area of high unmet medical need (Figure 9).
Phase 2 clinical trial of CYP-001 in aGvHD, with patient enrolment completed (65 patients across the US, Europe, and Australia), primary evaluation expected to be completed in March 2026, and results anticipated around June 2026.
Additional advanced programs include CYP-004 in osteoarthritis (Phase 3), CYP-001 in kidney transplantation (Phase 1/2), and CYP-006TK in diabetic foot ulcers (Phase 1 completed).
Multiple programs supported by FDA regulatory engagement, including Orphan Drug Designation for CYP-001 in aGvHD.
Figure 9: CYP-001 (source: CYP)
Market Standing
Market Capitalisation: ~$94.98 million.
Industry Group: Pharmaceuticals, Biotechnology & Life Sciences.
ASX Listing Date: 20 December 2007, reflecting a long-standing presence on the ASX through multiple clinical development cycles.
Share price performance shows a clear upward re-rating from mid-2025 into early January 2026, supported by increased trading volumes, indicating growing investor attention ahead of key Phase 2 and Phase 3 clinical readouts.
Figure 10: CYP’s Share Price & Trading Volume (Jan 2025 – Jan 2026) (source: ASX)
Near-term Milestones to Watch
Clinical data readouts: Interim and topline results from late-stage trials remain the most significant value inflection points, particularly where programs are moving from Phase 2 into Phase 3 or toward regulatory decision-making.
Regulatory progress: FDA interactions, trial approvals, and pathway clarity (including orphan or fast-track designations) will continue to shape timelines and risk profiles across the sector.
Commercial execution: For companies with approved products or live deployments, evidence of adoption, contract expansion, and revenue traction will be key indicators of execution beyond validation.
Partnerships and funding: Licensing discussions, strategic collaborations, and balance sheet updates will be important signals of how companies intend to fund the next phase of growth without excessive dilution.
Samso Concluding Comments - ASx Healthcare
Investors all know that the art of investment is not a process that has set rules. Every element is different, and there is never one business, one company, or an investment idea that is a linear event. Share prices often move ahead of fundamentals, lag behind progress, or respond sharply to single data points. This is why understanding where a company sits — clinically, commercially, and structurally — is critical before reacting to market movement.
What this snapshot tries to highlight is the diversity of pathways within the ASX healthcare sector. Some companies are transitioning from regulatory de-risking into commercial execution, while others remain value-driven by upcoming clinical data. These are very different investment propositions, even if they sit under the same sector label.
Market capitalisation alone does not tell the full story. A company’s revenue visibility, trial design quality, regulatory engagement, and execution discipline all contribute to how risk is priced over time. These factors tend to matter far more than short-term price volatility. The final piece of the problem is to understand that the best research, the best mathematical prediction, will ultimately be all undone by a black swan event that will always come from a place nobody expects.
Ultimately, this snapshot is firstly an introduction to the Samso community that may not have come across the companies, and it hopefully will help potential investors step back from headlines and focus on structure. Understanding the business model, the clinical roadmap, and the market context provides a stronger foundation for decision-making than reacting to price action alone.
The Samso Way – Seek the Research
Here at Samso, we pride ourselves on delivering content for investors that is independent and informed by over three decades of experience in the industry. Our content is well-researched and is only created if I see merit in discussing the company's story.
Our mission is simple: cut through the noise and spotlight what matters—genuine stories, grounded insights, and real opportunity.
Our content is well-researched and is only created if the team sees merit in discussing the company or concept. Investors can explore our three core platforms:
There may be numerous paths to success in investing, but the common thread among successful individuals is that they remain committed to making informed decisions. Equip yourself with the right knowledge and tools, and you will be well on your way to achieving your financial goals.
Most importantly, investors need to be absolutely diligent in understanding their own risk-reward tolerance and capabilities. Never bite off more than you can chew. As they say, Rome wasn’t built in a day, and the Great Wall stood because it took centuries to complete.
The Samso Philosophy:
Stay curious. Stay sharp. And remember—digging deeper always uncovers the real value.
In Life, there is no such thing as a Free Lunch.
Never bite off more than you can chew is my parting comment.
Happy Investing, and the only four-letter word you need to know is DYOR.
To support our independent nature of our work, please head over to our Support Page and give us a helping hand in any of the ways listed. This is a new initiate for the Samso Platform, and it was always the concept of Samso when we started this journey in 2018.
Disclaimer
The information or opinions provided herein do not constitute investment advice, an offer or solicitation to subscribe for, purchase or sell the investment product(s) mentioned herein. It does not take into consideration, nor have any regard to your specific investment objectives, financial situation, risk profile, tax position and particular, or unique needs and constraints.
Share to Grow: Your Bonus
Samso has just released an eBook: How to Add Value to your Share Portfolio
A lesson on geological models sought by mining companies that gives insight and an understanding of which portfolios are better - and potentially more lucrative – investments. Click here to download this eBook.
If you find this article informative and useful, please help me share the information. I try to write about topics that are interesting and have the potential to be of investment value. It is not easy to find stories that fit those parameters. If you or your organisation sees the benefit of what Samso is trying to achieve and has a need to share your journey, please get in touch with me at noel.ong@samso.com.au.
Samso is a trusted platform that equips dedicated investors with up-to-date industry knowledge and insights from top CEOs and thought leaders. By staying informed on business advancements and market trends, investors can enhance their financial decisions through a combination of expert guidance and their own research.
Comments